Sutton Coldfield, United Kingdom

Carl Rye

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Sutton, GB (2017)
  • Sutton Coldfield, GB (2019 - 2023)

Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Carl Rye

Introduction

Carl Rye is a notable inventor based in Sutton Coldfield, GB. He has made significant contributions to the field of therapeutic agents, particularly in the treatment and prevention of proliferative diseases such as cancer. With a total of 4 patents to his name, Rye's work is recognized for its potential impact on medical science.

Latest Patents

Rye's latest patents include innovative compounds known as fused 1,4-dihydrodioxin derivatives, which serve as inhibitors of heat shock transcription factor 1 (HSF1). These compounds are designed to be therapeutic agents for the treatment and prevention of proliferative diseases, including cancer. The patents detail the processes for preparing these compounds and the pharmaceutical compositions that incorporate them.

Career Highlights

Carl Rye is associated with Cancer Research Technology Limited, where he continues to advance his research and development efforts. His work focuses on creating effective solutions for serious health challenges, particularly in oncology.

Collaborations

Rye collaborates with esteemed colleagues such as Keith Jones and Nicola Chessum, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Carl Rye's contributions to the field of medical research through his patents and collaborations highlight his commitment to advancing therapeutic solutions for cancer treatment. His innovative work continues to inspire and pave the way for future developments in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…